Daunorubicin

CHEMBL178 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
527.5 g/mol
LogP
1.8
Phase
4

An anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, blocking DNA replication and causing cancer cell death; used primarily for acute myeloid and acute lymphoblastic leukemia. Like other anthracyclines, cumulative cardiotoxicity is a major dose-limiting concern.

分子量

527.5000 g/mol

LogP

1.80

TPSA

186.00 Ų

Lipinski 五规则

不符合

治疗领域

作用机制

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1

InChI

InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1

Molecular Formula

C27H29NO10

HBD / HBA

5 / 11

可旋转键数

4

重原子数

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

An anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, blocking DNA replication and causing cancer cell death; used primarily for acute myeloid and acute lymphoblastic leukemia. Like other anthracyclines, cumulative cardiotoxicity is a major dose-limiting concern.

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Yes, Daunorubicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL178. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 30323. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.